Moncef Slaoui, PhD has led the development of numerous vaccines that are in use worldwide. He is currently a partner at Medicxi, a European venture capital firm.
Previously, Slaoui served as chairman of pharmaceutical R and D and the vaccines division at GSK.
While there, Slaoui engineered a vaccine pipeline, including vaccines against pneumococcal disease and rotavirus, as well as vaccines against shingles and Human Pappiloma Virus.
Slaoui earned a PhD in molecular biology and immunology from the Université Libre de Bruxelles in Belgium, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine in Boston, and was a professor of Immunology at the University of Mons, Belgium.
The Human Vaccines Project's mission is to decode the human immune system to accelerate the development of vaccines and immunotherapies against major global diseases.
It brings together academic research centers, industrial partners, nonprofits and governments to address the primary scientific barriers to developing new vaccines and immunotherapies.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma